Sanofi-aventis

Sanofi

Mitsubishi Pharma Corporation

Mitsubishi Tanabe Pharma Corporation

Sanofi-synthelabo

Synthelabo

Syntex (u.s.a.) Inc.

Mitsubishi Electric Corporation

Tanabe Pharma Corporation

Sanotl-aventis

Mitsubishi Pharma Corporation Tokyo

Alistair Lochead

Mourad Saady

Philippe Yaiche

Alain Nedelec

Franck Slowinski

Julien Vache

Odile LeClerc

Samir Jegham

Thierry Gallet

Frederic Galli

Aude Fayol

Frédéric Galli

Patrick Andre Lardenois

Nathalie Chereze

Fr&eacute;d&eacute;ric Galli

Corinne Veronique

Séverine Marguerie

Axelle Samson

Ahmed Abouabdellah

Antonio Almario Garcia

Jean Jeunesse

Luc Even

Adrien Tak Li

Pascal George

Axelle Solignac

Michel J Navet

Peter E Hicks

Omar Ben Ayad

Jean Claude Muller

Andre Pierre Dumas

Jean Jacques Koenig

Odile Leclerc

Colombe Denys

Laurence De Cruz

Yves Guminski

Mourad Saadi

A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein X, R1, R2, R3, R4, and m are defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates thereof and their use in therapeutics.

Substituted alkyl pyrimidin-4-one derivatives

Pyrimidone derivatives of formula (I) wherein R1, R2, R3, R4, R5, and R6 are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I) and their use in therapeutics.

Substituted pyrimidone derivatives

The invention relates to a compound of the general formula (I) in which Ris a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C-alkyl, C-alkoxy, NRRgroup; m, n, o and p are independently an integer equal to 0, 1, 2 or 3; A is a covalent bond or a C-alkylene group; Ris an optionally substituted aryl or heteroaryl group; Ris a hydrogen or fluorine atom or a C-alkyl group or a trifluoromethyl group; Ris an optionally substituted 5-member heterocyclic compound; the compound being in the form of a base or acid addition salt. The invention also relates to the therapeutic use thereof. 

Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof

The invention relates to compounds of the general formula (I) where: Ris a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C-alkyl, C-alkoxy, or NRRgroup; m and p have a value of 1; n and o have the same value which is 0 or 1; A is a covalent bond or a C-alkylene group; Ris an optionally substituted aryl or heteroaryl group; Ris a hydrogen or fluorine atom or a C-alkyl group or a trifluoromethyl group; Ris an optionally substituted 5-membered heterocyclic compound; wherein the compounds can be in the state of a base or an acid addition salt. The present invention can be used in therapeutics. 

5-membered heterocyclic compound cyclopenta[C]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof

The invention relates to compounds of the general formula (I): wherein R, m, n and o are as defined herein. The invention also relates to a method for preparing the same and to the application in therapy.

Azabicycloalkane derivatives, preparation thereof and use thereof in therapy

A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein Y, R1, R2, R3, and R4 are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates thereof and their use in therapeutics.

Substituted pyrimidin-4-one derivatives

The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof:  Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

Arylamide pyrimidone compounds

The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

Heteroarylamide pyrimidone derivatives

Arylamide pyrimidone derivatives

Heteroarylamide pyrimidone compounds

Triazinone derivatives represented by formula (I) wherein:

Substituted triazinone derivatives

The invention relates to compounds having general formula (I), wherein R is as defined herein.  The invention also relates to acid addition salt, a hydrate or a solvate of compounds of formula (I). The invention further relates to the method of preparing said compounds and to the use of same in therapeutics.

Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics

Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics

The present invention discloses and claims compounds of general formula in which X, R, P, Q, R and W are as described herein. The compounds of the invention are useful in a variety of therapeutic applications.

1,4-diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof

The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein:Y, Z, R1, R2, R3, R4, R5 and n are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

Substituted arylamide diazepinopyrimidone derivatives

Growing community of inventors

Charenton le Pont, France

Alistair Lochead